In fact, the latest guidelines suggest the use of CDK4/6 inhibitors combined with AIs or fulvestrant as the standard therapy for ER+ advanced breast cancer in both pre- and post-menopausal women [4]. This evidence concerns the gene ESR1 and breast carcinoma.